An ad hoc committee will conduct a study and provide a report with findings and recommendations on the status and utilization of molybdenum-99 for medical use. This study will provide

1. A list of facilities that produce molybdenum-99 for medical use, including an indication of whether these facilities utilize highly enriched uranium.
2. A review of international production of molybdenum-99 over the previous 5 years, including whether any new production was brought online; whether any facilities halted production unexpectedly; and whether any facilities used for production were decommissioned or otherwise permanently removed from service.
3. An assessment of progress made in the previous 5 years toward establishing domestic production of molybdenum-99 for medical use, including the extent to which other medical isotopes that have been produced with molybdenum-99, such as iodine-131 and xenon-133, are being used for medical purposes.
4. The adequacy of molybdenum-99 supplies to meet future domestic medical needs, particularly in 2016 and beyond.
5. An assessment of the progress made by the Department of Energy and others to eliminate worldwide use of highly enriched uranium in reactor targets and medical isotope production facilities. This assessment should identify key remaining obstacles for eliminating highly enriched uranium from reactor targets and medical isotope production facilities and recommend steps that could be taken to overcome the identified obstacles.